Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIFANG
NCT07520162Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by AstraZeneca. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07520162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520162.